These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32562684)

  • 1. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.
    Volc D; Poewe W; Kutzelnigg A; Lührs P; Thun-Hohenstein C; Schneeberger A; Galabova G; Majbour N; Vaikath N; El-Agnaf O; Winter D; Mihailovska E; Mairhofer A; Schwenke C; Staffler G; Medori R
    Lancet Neurol; 2020 Jul; 19(7):591-600. PubMed ID: 32562684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.
    Meissner WG; Traon AP; Foubert-Samier A; Galabova G; Galitzky M; Kutzelnigg A; Laurens B; Lührs P; Medori R; Péran P; Sabatini U; Vergnet S; Volc D; Poewe W; Schneeberger A; Staffler G; Rascol O;
    Mov Disord; 2020 Nov; 35(11):1957-1965. PubMed ID: 32882100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Novak P; Schmidt R; Kontsekova E; Zilka N; Kovacech B; Skrabana R; Vince-Kazmerova Z; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Winblad B; Novak M
    Lancet Neurol; 2017 Feb; 16(2):123-134. PubMed ID: 27955995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.
    Poewe W; Volc D; Seppi K; Medori R; Lührs P; Kutzelnigg A; Djamshidian A; Thun-Hohenstein C; Meissner WG; Rascol O; Schneeberger A; Staffler G; ; ; Poewe W; Seppi K; Djamshidian A; deMarzi R; Heim B; Mangesius S; Stolz R; Wachowicz K; Volc D; Thun-Hohenstein C; Riha C; Schneeberger A; Bürger V; Galabova G
    J Parkinsons Dis; 2021; 11(3):1079-1089. PubMed ID: 34092654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial.
    Goldblatt D; Southern J; Andrews NJ; Burbidge P; Partington J; Roalfe L; Valente Pinto M; Thalasselis V; Plested E; Richardson H; Snape MD; Miller E
    Lancet Infect Dis; 2018 Feb; 18(2):171-179. PubMed ID: 29174323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.
    Jankovic J; Goodman I; Safirstein B; Marmon TK; Schenk DB; Koller M; Zago W; Ness DK; Griffith SG; Grundman M; Soto J; Ostrowitzki S; Boess FG; Martin-Facklam M; Quinn JF; Isaacson SH; Omidvar O; Ellenbogen A; Kinney GG
    JAMA Neurol; 2018 Oct; 75(10):1206-1214. PubMed ID: 29913017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
    Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
    Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
    Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
    Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
    Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
    Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial.
    van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR
    Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.
    Yu HJ; Thijssen E; van Brummelen E; van der Plas JL; Radanovic I; Moerland M; Hsieh E; Groeneveld GJ; Dodart JC
    Mov Disord; 2022 Jul; 37(7):1416-1424. PubMed ID: 35426173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.
    Levin J; Maaß S; Schuberth M; Giese A; Oertel WH; Poewe W; Trenkwalder C; Wenning GK; Mansmann U; Südmeyer M; Eggert K; Mollenhauer B; Lipp A; Löhle M; Classen J; Münchau A; Kassubek J; Gandor F; Berg D; Egert-Schwender S; Eberhardt C; Paul F; Bötzel K; Ertl-Wagner B; Huppertz HJ; Ricard I; Höglinger GU;
    Lancet Neurol; 2019 Aug; 18(8):724-735. PubMed ID: 31278067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study.
    Vitek JL; Jain R; Chen L; Tröster AI; Schrock LE; House PA; Giroux ML; Hebb AO; Farris SM; Whiting DM; Leichliter TA; Ostrem JL; San Luciano M; Galifianakis N; Verhagen Metman L; Sani S; Karl JA; Siddiqui MS; Tatter SB; Ul Haq I; Machado AG; Gostkowski M; Tagliati M; Mamelak AN; Okun MS; Foote KD; Moguel-Cobos G; Ponce FA; Pahwa R; Nazzaro JM; Buetefisch CM; Gross RE; Luca CC; Jagid JR; Revuelta GJ; Takacs I; Pourfar MH; Mogilner AY; Duker AP; Mandybur GT; Rosenow JM; Cooper SE; Park MC; Khandhar SM; Sedrak M; Phibbs FT; Pilitsis JG; Uitti RJ; Starr PA
    Lancet Neurol; 2020 Jun; 19(6):491-501. PubMed ID: 32470421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.